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Objective: Abnormal trophoblastic invasion and impaired placentation have a crucial role in the etiopathogenesis of preeclampsia (PrE). 
Trophoblastic cells are involved in invading the maternal decidua and remodelling of the spiral arteries with matrix metalloproteinase-14 (MMP-
14). MMP-14 cleavage of endoglin releases its extracellular region, the soluble form of endoglin (s-ENG), into the maternal circulation. In PrE, 
there is a relationship between endothelial dysfunction and s-ENG concentration. The aim was to determine and compare the serum levels of 
s-ENG and MMP-14 in different groups of PrE patients and healthy subjects.
Material and Methods: The study included 30 patients with late-onset preeclampsia (L-PrE) (group 1; gestational age ≥34 weeks), 33 patients 
with normal pregnancy (group 2; gestational age ≥34 weeks), 31 patients early-onset preeclampsia (E-PrE) (group 3; gestational age <34 weeks), 
and 31 patients with normal pregnancy (group 4; gestational age <34 weeks). s-ENG and MMP-14 concentrations measured using enzyme-linked 
immunosorbent assays were compared.
Results: In all groups, MMP-14 concentrations decreased with increasing gestational age. s-ENG concentrations were highest in the E-PrE group. 
In groups 1 and 3, 29 had mild PrE while 32 suffered severe PrE and s-ENG concentrations did not differ between mild and severe preeclampsia 
(p=0.133). However, there was a significant difference in MMP-14 concentration comparing mild with severe PrE (3.11±0.61 vs 3.54±1.00; 
p=0.047, respectively). There was no correlation between s-ENG and MMP-14 concentrations. 
Conclusion: MMP-14 and s-ENG concentrations can be predictive biomarkers for the diagnosis of PrE. Maternal serum MMP-14 concentration 
may be a biomarker for determining the severity of PrE. (J Turk Ger Gynecol Assoc 2021; 22: 29-36)
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Introduction
Preeclampsia (PrE) remains an important obstetric syndrome 
and has a major effect on maternal/infant morbidity/mortality 
worldwide (1). The main features include protein leakage into 
urine and new-onset gestational hypertensive disease, or other 
signs/symptoms of PrE in the absence of proteinuria after 20 
weeks’ gestation. Although improvements have been reported 
in the diagnosis and treatment of PrE in previous studies, there 
are still many unanswered questions. In PrE, the reduced 
capacity of extravillous trophoblasts (EVTs) for invasion into 
the spiral arteries results in an inadequately perfused fetal-
placental unit. When the embryo is implanted, EVTs invade 
the decidua and remodel spiral arteries getting as deeply as 
the inner third of the myometrium. Matrix metalloproteinases 
(MMPs) enable the infiltration of EVTs into the uterine wall. 
Decidual stromal cells produce high concentrations of MMPs, 
enhancing the invasiveness of the EVTs (2,3). Dysregulation 
of MMPs causes inadequate trophoblast invasion, inadequate 
uterine and spiral artery remodeling, which may result in the 
development PrE (4,5).
MMPs are calcium- and zinc-dependent proteases that break 
down different components of the extracellular matrix 
(ECM). MMPs are key to the mediation of apoptosis, cell 
proliferation, cell-cell adhesion, cell migration and invasion, 
and tissue remodeling (6). The presence of MMP-14 has 
been demonstrated in the membrane of trophoblast and 
vascular endothelial cells (7). In normal pregnancy, there is a 
notable increase in MMP-14 concentration in the last trimester 
versus the first trimester (8). In PrE, the abnormal release of 
vasoactive factors such as MMP-1 and MMP-14 occurs near the 
end of pregnancy, thereby contributing to the development of 
hypertension. MMP-1 and MMP-14 have also been investigated 
in other obstetric syndromes, such as premature rupture of 
membranes (PROM) and preterm labor. The role of MMPs 
has been investigated in a wide range of conditions including 
inflammation and malignant growth, as well as reproductive 
and neurologic disorders (2). Further, analysis of gene 
expression demonstrated that both MMP-14 and endoglin gene 
expression was increased in PrE (9).
Endoglin (CD105) is an integral, membrane-bound 
glycoprotein and one of its functions is as a co-receptor 
for transforming growth factor-beta. High endoglin 
concentrations on the syncytiotrophoblasts in patients with 
severe PrE have been reported using western blot analysis 
and immunohistochemistry staining. A soluble form of 
endoglin (s-ENG) has been demonstrated in human blood. 
s-ENG is released from endothelial tissues, phagocytes, 
syncytiotrophoblasts, and smooth muscle cells. The role and 
direct molecular mechanism of s-ENG is not clear; however, it 
is capable of reducing angiogenesis (10,11). MMP-14 cleavage 
of endoglin releases s-ENG into the maternal circulation. The 
rise in s-ENG concentration in PrE is proportional to the severity 
of the disease and reduces after delivery. The relationship 
between endothelial dysfunction following poor placentation 
and s-ENG has also been shown in PrE. Several studies have 
shown that MMP-14 has importance in the reduction of 
s-ENG concentrations leading to alleviation of the clinical 
manifestations of PrE (2,8).
There is currently no mechanism to predict PrE or confirm 
PrE diagnosis before clinical occurrence. Many studies have 
investigated MMP-14 in PrE. However, there are no studies 
measuring serum MMP-14 concentrations by enzyme-linked 
immunosorbent assay (ELISA) in PrE. ELISA is a less-invasive, 
easy, fast, and inexpensive method. The aim was to evaluate 
the values of maternal serum MMP-14 and s-ENG in patients 
with PrE compared to healthy pregnancies, and to investigate 




Our subjects were prospectively recruited from the Clinic of 
Obstetrics and Gynecology at Cengiz Gökçek Public Hospital, 
Gaziantep, Turkey, between January 2018 and December 
2018. This study was conducted according to the Declaration 
of Helsinki, and the Institutional Ethical Review Board of 
Gaziantep University Faculty of Medicine approved the study 
(approval number: 2018/91). A total of 138 pregnant women 
were recruited to the study, out of which 13 were excluded 
on grounds of incomplete fetomaternal details, refusal to 
participate in the study, and an SGA fetus in the control group 
(Figure 1). The remaining 125 women were divided into 
groups as follows. Thirty women with late-onset (≥34 weeks 
of gestation) preeclampsia (L-PrE) formed group 1; 33 healthy 
women at ≥34 weeks gestation were recruited to group 2; 31 
women with early-onset (<34 weeks gestation) preeclampsia 
(E-PrE) formed group 3; and 31 healthy women at <34 
weeks pregnancy were recruited to group 4. Groups 2 and 4 
were matched for maternal and gestational age with groups 
1 and 3, respectively. The control groups comprised women 
with healthy pregnancies who presented to our hospital for 
routine obstetric examination. All subjects were informed 
about the study and each gave written consent. Gestational 
age assessment was based on last menstrual period or first-
trimester ultrasonographic obstetric measurements.
The diagnosis of PrE was based on the presence of proteinuria 
(urinary excretion of protein ≥300 mg in a 24-hour urine 
specimen, or proteinuria ≥1+ in dipstick) and a maternal 
blood pressure of ≥140/90 mmHg (a mean of two blood 
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pressure measurements obtained six hours apart), occurring 
after 20 weeks of gestation in a previously normotensive 
woman, as defined by the Committee on Terminology of the 
American College of Obstetricians and Gynecologists. Mild PrE 
was defined as a blood pressure between ≥140/90 mmHg and 
160/110 mmHg (for systolic and/or diastolic measurement) and 
if values exceeded 160/110 mmHg it was accepted as severe, 
as previously described (12). Small for gestational age (SGA) 
newborns were accepted as birth weight <10th percentile 
for gestational age with Turkey’s national nomogram as the 
reference for fetal growth (13). Maternal body mass index 
(BMI) was calculated in kg/m2 using the standard formula. 
Exclusion criteria for both groups were: pregnant women with 
any systemic disease, such as chronic hypertension, diabetes 
mellitus, thyroid diseases, liver and kidney diseases; use of any 
kind of medication throughout pregnancy; use of any medication 
for PrE treatment at the time of first admission; history of 
pregnancies complicated by PROM or chorioamnionitis; fever 
at the time of first admission; fetal congenital abnormalities 
or genetic syndromes; smoking during pregnancy; multiple 
gestation; and active labor.
Each pregnant woman had obstetric ultrasound examination 
and fetal/maternal assessment, which were conducted by 
a single obstetrician-gynecologist specialist (AO). Obstetric 
anamneses were obtained from all pregnant women. 
Demographic data, such as age, gravidity, parity, BMI, and 
gestational age were recorded. Maternal venous blood 
samples were taken for measurement of s-ENG and MMP-
14 concentrations after the diagnosis of PrE in the outpatient 
clinic. The samples were immediately centrifuged at 1500 g 
for 10 min, and serum samples were separated and stored at 
-80 °C until required for analysis. All patients with E-PrE were 
hospitalized. After hospitalization, a betamethasone injection 
(12 mg) was administered without delay. Pregnancy was 
terminated immediately in the event of urgent fetal/maternal 
situations such as severe PrE development or fetal distress. 
Otherwise, maternal blood pressure was measured at least 
every 4 hours during rest with the arm held at the level of the 
heart. Hypertension can persist for short intervals in patients 
with diastolic and/or systolic blood pressure ≥110 mmHg and 
≥160 mmHg, respectively, to facilitate timely anti-hypertensive 
treatment. In cases of E-PrE, delivery should be delayed for 
at least 48 hours if maternal and fetal status permit. During 
this period, betamethasone injections for lung maturation 
(two doses of 12 mg at 24-hour intervals) were administered. 
All patients with L-PrE were also hospitalized and their 
pregnancies were terminated. Women with uncomplicated 
pregnancies were randomly selected at the same time as the 
Figure 1. Flow chart of the pregnant women recruited in the study
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case selection was performed to serve as controls. The samples 
from the control groups were obtained during routine obstetric 
examinations in the last trimester of pregnancy. These women 
were then followed up until delivery. The four groups were 
compared in terms of maternal age, BMI, gravida, parity, week 
of gestation, systolic/diastolic blood pressure, full blood count, 
liver function tests including alanine aminotransferase and 
aspartate aminotransferase, blood urea nitrogen, creatinine, 
s-ENG, MMP-14 and total protein in spot urine sample, and 
infant weight at delivery.
Serum MMP-14 and s-ENG analysis
MMP-14 concentrations were assessed using a commercial 
ELISA kit, the Human MMP-14 ELISA Kit (Rel Assay Diagnostics, 
Gaziantep, Turkey), in accordance with the manufacturer’s 
instructions. This ELISA kit (sensitivity range: 0.05 ng/mL; 
detection range: 0.1-30 ng/mL) is based on the principle 
of biotin double-antibody sandwich technique. The intra- 
and inter-assay variation coefficients were <8% and <10%, 
respectively. A commercial ELISA kit was also used for the 
assessment of s-ENG concentrations, specific for the detection 
of human s-ENG with high sensitivity and specificity (Rel Assay 
Diagnostics, Gaziantep, Turkey). The kit (sensitivity range: 0.23 
ng/mL; detection range: 0.5-200 ng/mL) also used a sandwich-
ELISA principle. The intra- and inter-assay variation coefficients 
were <8% and <10%, respectively.
Statistical analysis
Statistical analyses were performed using SPSS for Windows, 
version 25.0, software package (IBM Inc., Armonk, NY, USA), 
and p values <0.05 were accepted as statistically significant. 
Results were presented as mean ± standard deviation (SD) 
after investigating normality distribution by Shapiro-Wilk test. 
In the analyses of the variables, the Student’s t-test was used for 
comparing two groups. ANOVA was used for the comparison 
of four groups. As a result of variance analysis, Tukey HSD test, 
one of the post-hoc tests, was used to determine the difference 
between the groups. In addition, the demographic data of the 
variables were investigated using frequency analyses.
Results
A total of 61 pregnant women with PrE were included. The 
control groups included 64 healthy pregnant women. The 
demographic data of the groups were compared (Table 1). 
There was no significant difference between maternal age, 
gravidity, and parity, but there was a significant difference 
between the groups for BMI, gestational age, systolic blood 
pressure, diastolic blood pressure, and birth weights (p<0.05). 
The laboratory results of the study and control groups are 
shown in Table 2. MMP-14 and s-ENG concentrations differed 
between the groups, as shown in Table 2 and Figure 2, 3. MMP-
14 concentrations did not differ between group 1 and group 2, 
nor did they differ between group 3 and group 4. Thus, MMP-
14 concentrations were the same in women with PrE and 
healthy pregnancies matched for gestational age but did differ 
between earlier and later pregnancies, that is between <34 
weeks and ≥34 weeks gestation. In all pregnant women, as the 
gestational age increased, MMP-14 concentrations in maternal 
serum decreased.
The highest concentrations of s-ENG were found in the E-PrE 
group. No differences were detected between s-ENG and MMP-
14 concentrations in mild (n=21) and severe PrE (n=9) in the 
L-PrE group (p=0.829, p=0.210, respectively). In addition, 
no differences were detected between s-ENG and MMP-14 
concentrations in mild (n=8) and severe PrE (n=23) in the 
E-PrE group (p=0.887, p=0.739, respectively). When early 
and late PrE groups (group 1 and group 3) were compared, 
no differences were detected between s-ENG concentrations 
in mild (n=29) and severe PrE (n=32) (p=0.133). However, 
there was a significant difference in MMP-14 concentrations 
in pregnancies affected by mild or severe PrE (3.11±0.61 vs 
3.54±1.00, p=0.047, respectively) (Table 3).
When the patients with (n=10) and without (n=115) SGA 
infants were compared, no differences were found in s-ENG 
and MMP-14 concentrations (p=0.133, p=0.969, respectively). 
When the patients with (n=15) and without (n=110) new-
onset cerebral or visual disturbances were compared, there 
were again no differences in s-ENG and MMP-14 concentrations 
(p=0.528, p=0.573, respectively). When the patients with (n=8) 
and without (n=117) right upper quadrant or epigastric pain 
were compared, no difference was found in s-ENG and MMP-
14 concentrations (p=0.162, p=0.154, respectively). When 
those who had first gravidity (31 patients) and gravidity >1 (94 
patients) were compared, no differences were found between 
the s-ENG and MMP-14 concentrations (p=0.855, p=0.364, 
respectively). No difference was found in serum concentrations 
of s-ENG and MMP-14 when subjects were compared in terms 
of BMI [<30 kg/m2 (n=56) and ≥30 kg/m2 (n=69)] p=0.373 
and p=0.873 for s-ENG and MMP-14, respectively or for maternal 
age [<35 years (n=100) and ≥35 years (n=25)] p=0.167 and 
p=0.625 for s-ENG and MMP-14 respectively. No statistically 
significant correlation was detected between s-ENG and MMP-
14 concentrations (p>0.05).
Discussion
In the present study, maternal blood concentrations of 
s-ENG and MMP-14 were evaluated in order to examine the 
association between diagnoses of L-PrE/E-PrE, the severity 
of PrE, and these biomarkers. It was found that serum s-ENG 
and MMP-14 concentrations differed significantly between the 
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two PrE groups and their respective matched control groups. 
The concentrations of s-ENG were at the highest in the E-PrE 
group (group 3) in which severe PrE was present. MMP-14 
concentrations, on the other hand, were found to be highest in 
severe PrE cases.
The contact between the placenta and the decidua ensures 
metabolic exchange between the fetus and the mother. 
Trophoblast cells of the embryo initially attach to the uterine 
epithelium. Trophoblasts differentiate into EVTs, which 
degrade the uterine epithelium basement membrane 
and ECM, then migrate into the decidual stroma. EVTs are 
characterized by their invasiveness, ensuring sufficient contact 
with the maternal circulation. Unsurprisingly, this invasion 
stage is under strict biological control and restricted to the 
decidua and the proximal third of the myometrium in healthy 
pregnancies. When this invasive process is dysregulated fetal 
Table 1. The demographic data of the groups
Variables












Age (years) 28.9±6.4 25.8±6.0 29.1±6.6 28.9±6.6 0.122 - -
BMI (kg/m2) 32.2±5.4a 28.6±4.9b 31.3±5.0ab 29.5±4.7ab 0.020
Group 1-group 2 0.026
Group 1-group 3 0.473
Group 1-group 4 0.137
Group 2-group 3 0.147
Group 2-group 4 0.915
Group 3-group 4 0.463
Gestational age 
(weeks)
37.2±1.5a 37.7±1.5a 31.1±2.2b 30.5±2.0b 0.001
Group 1-group 2 0.753
Group 1-group 3 0.001
Group 1-group 4 0.001
Group 2-group 3 0.001
Group 2-group 4 0.001
Group 3-group 4 0.555
Gravidity (n) 3.3±2.4 3.5±5.4 3.1±1.7 3.7±2.3 0.887
Parity (n) 1.9±1.9 1.5±1.3 1.5±1.4 1.9±1.7 0.620
Systolic pressure 
(mmHg)
160±18b 105±10c 173±18a 102±10c 0.001
Group 1-group 2 0.001
Group 1-group 3 0.017
Group 1-group 4 0.001
Group 2-group 3 0.001
Group 2-group 4 0.974
Group 3-group 4 0.001
Diastolic pressure 
(mmHg)
103±10b 65±6c 110±11a 65±7c 0.001
Group 1-group 2 0.001
Group 1-group 3 0.047
Group 1-group 4 0.001
Group 2-group3 0.001
Group 2-group 4 0.979
Group 3-group 4 0.001
Birth weight 
(grams)
2960±691a 3249±483a 1650±467b 3172±346a 0.001
Group 1-group 2 0.177
Group 1-group 3 0.001
Group 1-group 4 0.371
Group 2-group 3 0.001
Group 2-group 4 0.930
Group 3-group 4 0.001
L-PrE group 1: Late-onset preeclampsia patient group, Control group 2: Late-onset preeclampsia control group, E-PrE group 3: Early-onset preeclampsia 
patient group, Control group 4: Early-onset preeclampsia control group, Age: Maternal age, BMI: Body mass index, Gestational age: Gestational age at the 
time of recruitment, Syst TA: Systolic blood pressure, Diast TA: Diastolic blood pressure, n: Number, SD: Standard deviation, p<0.05 indicates statistical 
significance, a,b,c: Different letters symbolize the difference between the groups
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growth restriction and PrE may result. Invasive processes are 
generally assisted by the expression and activity of MMPs (8). 
EVTs also reach and remodel the spiral arteries, transforming 
them into low resistance vessels, a process necessary to allow 
an adequate blood supply to the fetus. It has been shown that 
this process is regulated by MMP-14 and MMP-15, mediated by 
endothelin-1 in a low oxygen environment (2-3% O2) (14). These 
pathologic changes constitute a process that starts in the first 
trimester, proceeds through a normal pregnancy period, and 
are finally reflected in an excessive clinical manifestation in the 
last trimester. These events consist of pathogenic factors that 
are produced in the placenta as a response to hypoxia, mixing 
Figure 2. Error plot showing the mean value of matrix 
metalloproteinase-14 in the groups
Figure 3. Error plot showing the mean value of soluble 
endoglin in the groups














Hemoglobin (g/dL) 12.0±1.4a 10.9±1.3b 11.9±1.3a 11.4±1.2ab 0.004 - -
Hematocrit (%) 36±3a 33±3c 35±3ab 33±2bc 0.001 - -
Platelets (x103/µL) 240±84 235±82 200±83 236±51 0.152 - -
WBC (µL/mL) 10.9±2.46 10.5±2.6 10.4±3.0 9.9±2.8 0.587 - -
BUN (mg/dL) 8.9±3.0ab 7.3±2.5bc 10.4±3.9a 6.4±2.1c 0.001 - -
Creatinine (mg/dL) 0.56±0.11b 0.47±0.09c 0.66±0.17a 0.46±0.08c 0.001 - -
ALT (IU/L) 20±30 10±4 22±30 11±4 0.054 - -
AST (U/L) 22±17 16±3 31±35 14±3 0.005 - -
Proteinuria (positivity on dipstick) 2.67±1.1a 0±0b 3.0±1.2a 0.0±0.2b 0.001 - -
s-ENG (ng/mL) 17.24±1.73a 18.49±2.01ab 22.64±12.98b 18.21±4.48ab 0.015
Group 1-group 2 0.892
Group 1-group 3 0.016
Group 1-group 4 0.086
Group 2-group 3 0.999
Group 2-group 4 0.064
Group 3-group 4 0.463
MMP-14 (ng/mL) 2.83±0.31a 2.93±0.43a 3.82±0.94b 3.81±1.26b 0.001
Group 1-group 2 0.957
Group 1-group 3 0.001
Group 1-group 4 0.001
Group 2-group 3 0.001
Group 2-group 4 0.001
Group 3-group 4 1.00
Group 1: Late-onset preeclampsia ≥34 weeks of gestation, Group 2: Healthy pregnancy ≥34 weeks of gestation, Group 3: Early-onset preeclampsia <34 
weeks gestation, Group 4: Healthy pregnancy <34 weeks of gestation, WBC: White blood cells, BUN: Blood urea nitrogen, ALT: Alanine aminotransferase, 
AST: Aspartate aminotransferase, Proteinuria: Spot urine proteinuria by dipstick test, s-ENG: Soluble endoglin, MMP-14: Matrix metalloproteinase-14, n: 
number, SD: Standard deviation, p<0.05 indicates statistical significance, a,b,c: Different letters symbolize the difference between the groups
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with the maternal blood and causing endothelial dysfunction. 
Despite the presence of abnormally high concentrations of 
excreted molecules, inflammatory factors, autoimmunity or 
anti-angiogenic processes are far more important (15).
Several authors have demonstrated that the ECM and MMP-
14 were vital regulators of angiogenesis (16,17). Placental 
MMPs may influence spiral artery remodeling in implantation. 
In PrE, MMPs have roles in prompting vasoconstriction, 
changes in vascular reactivity, and pathological damage to the 
endothelium. Thus, there has been an increase in interest in the 
pathological effect of the imbalance of angiogenic and/or anti-
angiogenic factors in PrE, including endoglin/s-ENG and MMP-
14. The close association between the location and expression 
levels of MMP-14 and the same features relating to endoglin 
has attracted much interest. MMPs have become important 
biomarkers for the identification of women with an elevated 
risk of developing PrE and also important biologic targets for 
treating this syndrome (1,7,18). The process of investigating 
MMP-14 tissue level and expression postpartum is complex, 
laborious and expensive. The aim of this study was to evaluate 
MMP-14 through direct measurements in maternal serum, a 
minimally invasive process, which can be repeated throughout 
pregnancy. The drawback of serum measurements of MMP-
14 are that these will not reflect tissue specific expression 
patterns in normal or PrE pregnancy, because of the significant 
membrane-binding properties of MMP-14 (19).
Zhang et al. (7) found that s-ENG concentrations were high 
in patients with severe PrE, and showed that this event was 
triggered by MMP-14, leading to the development of severe 
PrE. In contrast, Levine et al. (9) suggested that there were 
no important differences in s-ENG concentrations between 
women with mild PrE and severe PrE, reporting no correlation 
between s-ENG concentrations and the severity of PrE. However, 
it was also shown that there was an evident increase in s-ENG 
concentration, starting 2-3 months before the onset of PrE. 
They also reported that this increase was greater in E-PrE 
than in L-PrE (9,20). Sezer et al. (4) conducted a study in a PrE 
group comprising patients with E-PrE and L-PrE, and found 
that s-ENG concentrations in PrE were high in the maternal 
circulation and also umbilical cord blood. However, there was 
no difference between both preeclamptic groups regarding 
s-ENG concentration of the maternal circulation (4). Zafer et al. 
(11) compared s-ENG concentrations in maternal serum and 
amniotic fluid and reported that they were incompatible. All 
these findings suggest that all compartments have independent 
dynamics in terms of s-ENG. Moreover, it is possible that MMP-14 
may have independent dynamics, because of the close biological 
association with s-ENG. When all patients with severe PrE were 
analyzed, MMP-14 concentrations were found to be higher 
although s-ENG was not different. Interestingly, this might suggest 
that MMP-14 serum concentrations in PrE may be more significant 
than s-ENG. Although s-ENG and MMP-14 concentrations showed 
a similar pattern, the relationship between the two showed no 
statistically significant correlation. This may be because of the 
membrane-binding properties of MMP-14.
Study Limitation
We acknowledge strengths and limitations of the study. The 
most important limitation of our study was the small number 
of participants. We do not have the pre-pregnancy BMI of 
all participants. s-ENG and MMP-14 concentrations could 
have been examined in different compartments, such as the 
placenta, umbilical cord serum, and amniotic fluid. The other 
limitation was that there are no uterine artery Doppler studies 
in this study. The strengths of the study were that none of the 
patients had any treatment for PrE and only participants who 
were not in active labor were selected for the study. Another 
strength was the comparison of MMP-14 serum concentrations 
with s-ENG, which has a major role in angiogenesis and 
endothelial cell function.
Table 3. Clinical characteristics and biomarkers levels in the preeclampsia groups, group 1 (late PrE) and 
group 3 (early PrE). Biomarker data is given as mean ± SD
Variables Biomarkers
Group 1 and 3 Subgroups s-ENG (ng/mL) p MMP-14 (ng/mL) p


















Severe (n=32) 21.24±12.06 3.54±1.00





Yes (n=10) 22.43±12.38 3.33±1.04
s-ENG: Soluble endoglin, MMP-14: Matrix metalloproteinase-14, n: number, SD: standard deviation, p<0.05 indicates statistical significance
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Conclusion
Larger basic and clinical studies are necessary to assess 
whether MMPs have an important role in the pathophysiology 
of PrE. In addition, meta-analyses should be performed to 
investigate the predictive value of these enzymes as biomarkers 
or therapeutic targets. Finally, in view of the literature data, we 
believe that testing s-ENG is worthy of further investigation for 
the early diagnosis of PrE. In addition, it appears reasonable to 
investigate serum MMP-14 concentrations in predicting patients 
who will proceed to a severe form of PrE.
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